Shots:

• Celltrion along with Mirae Asset has signed a contract to invest $47M into Iksuda and become its largest shareholder. The companies have completed the execution of half of the investment and plan to execute the other half immediately after Iksuda completes certain milestones
• Celltrion expects that Iksuda's ADC pipeline will enable the development of diverse anticancer drugs such as Truxima and Herzuma. Additionally- the company plans to develop new drug substances by developing its ADC platform technology
• The company plans to maximize the pipeline by developing next-generation anticancer drugs while creating synergies with the Ab drugs the company owns

  | Ref: Iksuda Therapeutics | Image: Celltrion